share_log

Redhill Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Redhill Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Redhill Biopharma | S-8：员工福利计划证券登记
美股SEC公告 ·  06/20 07:27

Moomoo AI 已提取核心信息

On June 20, 2024, Redhill Biopharma Ltd., a biopharmaceutical company, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC). The filing pertains to the registration of an additional 800,000,000 ordinary shares, which may be issued under the company's Amended and Restated Award Plan (2010). These shares are represented by American Depositary Shares and are par value NIS 0.01 per share. The company, incorporated in Israel, has its principal executive offices in Tel Aviv and an agent for service located in Raleigh, North Carolina. The registration statement incorporates by reference several documents, including the company's Annual Report on Form 20-F for the year ended December 31, 2023, and various reports on Form 6-K. The company has also detailed its indemnification policies for directors and officers, as well as the conditions under which it may provide insurance and exemptions as per Israeli law and the company's articles of association. The filing includes undertakings by the company regarding the registration statement and the potential need for post-effective amendments.
On June 20, 2024, Redhill Biopharma Ltd., a biopharmaceutical company, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC). The filing pertains to the registration of an additional 800,000,000 ordinary shares, which may be issued under the company's Amended and Restated Award Plan (2010). These shares are represented by American Depositary Shares and are par value NIS 0.01 per share. The company, incorporated in Israel, has its principal executive offices in Tel Aviv and an agent for service located in Raleigh, North Carolina. The registration statement incorporates by reference several documents, including the company's Annual Report on Form 20-F for the year ended December 31, 2023, and various reports on Form 6-K. The company has also detailed its indemnification policies for directors and officers, as well as the conditions under which it may provide insurance and exemptions as per Israeli law and the company's articles of association. The filing includes undertakings by the company regarding the registration statement and the potential need for post-effective amendments.
2024年6月20日，生物制药公司红山生物有限公司向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该申报涉及注册额外的8亿普通股，可根据公司的修订和重述奖励计划（2010年）发行。这些股票是由美国存托股份代表，每股面值为NIS 0.01。该公司在以色列注册，总部设在特拉维夫，以及服务代理位于北卡罗来纳州的罗利。注册声明通过参考包括公司2013年12月31日的20-F表格年度报告和6-K表格的各种文件来实现。该公司还详细说明了其董事和高管的赔偿政策，以及按照以色列法律和公司章程提供保险和豁免的条件。提交包括公司关于注册声明的承诺和可能需要发表有效性修订的声明。
2024年6月20日，生物制药公司红山生物有限公司向美国证券交易委员会（SEC）提交了S-8表格的注册声明。该申报涉及注册额外的8亿普通股，可根据公司的修订和重述奖励计划（2010年）发行。这些股票是由美国存托股份代表，每股面值为NIS 0.01。该公司在以色列注册，总部设在特拉维夫，以及服务代理位于北卡罗来纳州的罗利。注册声明通过参考包括公司2013年12月31日的20-F表格年度报告和6-K表格的各种文件来实现。该公司还详细说明了其董事和高管的赔偿政策，以及按照以色列法律和公司章程提供保险和豁免的条件。提交包括公司关于注册声明的承诺和可能需要发表有效性修订的声明。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间